Research programme: erythrocyte encapsulated tumour antigen immunotherapies - ERYtechAlternative Names: ERYMMUNE; Tumour vaccines - ERYtech
Latest Information Update: 10 Mar 2017
At a glance
- Originator ERYtech Pharma
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer